NervGen Pharma will ring the Nasdaq closing bell in New York City on January 22, 2026 to mark its Nasdaq listing.

NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that the Company will ring the closing bell at the Nasdaq Stock Market (Nasdaq) on Thursday, January 22, 2026 in New York City.

Adam Rogers, MD, Chairman and Interim Chief Executive Officer will be joined by members of the NervGen management team, Board of Directors, advisors, and other guests.

“We are honored to participate in the Nasdaq closing bell ceremony and highlight NervGen’s mission to transform the lives of individuals living with spinal cord injury by enabling the nervous system to repair itself,” said Adam Rogers, MD, Interim Chief Executive Officer of NervGen Pharma. “Becoming a Nasdaq-listed company represents a significant milestone in the growth and evolution of NervGen. This latest accomplishment was made possible through the unwavering support of our shareholders, physician and scientific collaborators, advocacy partners, the individuals and families who have placed their trust in NervGen by participating in our clinical research, and our dedicated management team and advisors.”

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon
COMTEX_472247191/2227/2026-01-22T18:55:45